-
Befotertinib Mesylate Capsules Approved for Marketing
2023-05-31
Recently, the Class I innovative product Befotertinib Mesylate Capsules (Chinese trade name: 赛美纳) of Betta Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Alfosbuvir Tablets Approved for Marketing
2023-05-17
Recently, the Class-1 innovative drug Alfosbuvir Tablets (Chinese trade name:圣诺迪) of Nanjing Sanhome Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Zuberitamab Injection Approved for Marketing
2023-05-17
Recently, the Zuberitamab injection (Chinese trade name: 安瑞昔) of Zhejiang BioRay Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of CD20 positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) for adult patients, and should be combined with standardized CHOP therapies (cyclophosphamide, doxorubicin, vincristine, prednisone).
-
COVID wave on decline, say experts
2023-06-16
The recent wave of COVID-19 is now trending downward, with experts saying China's medical system and the public have coped with the fresh outbreak in an orderly and calm manner.
-
China launches three-year campaign to fight Alzheimer's disease
2023-06-16
Health authorities in China have launched a nationwide campaign that will be carried out from 2023 to 2025 to promote the prevention and treatment of Alzheimer's disease (AD).
-
NMPA holds training on NRA for vaccines in Beijing
2023-06-13
The National Medical Products Administration (NMPA) held a special training session in Beijing from June 6 to 7, where experts from the World Health Organization (WHO) introduced the National Regulatory Authority (NRA) for vaccines.
